Philogen

Company Description

---

Founded in 1996, Philogen is an Italian-Swiss biotechnology company engaged in the discovery and development of biopharmaceutical products for the treatment of life-threatening conditions.

Philogen Group mainly discovers and develops targeted anti-cancer drugs, exploiting high-affinity ligands for tumor markers. These ligands – namely human monoclonal antibodies or small molecules – are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The main therapeutic strategy of the Group for the treatment of these diseases is the so-called “tumor targeting”.

Year founded

---

1996

Headquarters

---

Piazza La Lizza 7, 53100 Siena – Italy

Shares outstanding

---

40,611,111

IPO

---

Jan. 1, 2000

Stock exchange(s)

---

Borsa Italiana